What did @hollypetricevich0 actually say?
Holly posted a raw, clearly distressed video describing her first week on Mounjaro (tirzepatide) as "deathly ill" and borderline unbearable. She reported losing about four kilos in one week from side effects alone, experiencing constant nausea, gastrointestinal noise she could hear from outside her body, and a complete loss of appetite so severe that "any thought of food actually makes me feel like I need to vomit." She's considering stopping entirely, framing it as a choice between her health and her ability to function as a mother of two. She explicitly pushes back on the common advice to "just push through," saying that's not realistic for her life.
There's no exaggeration here for dramatic effect. These are documented, common side effects. The question is whether her experience represents a typical adjustment period or a signal that tirzepatide isn't the right fit for her.
Does the science back this up?
Yes, largely. GI side effects on tirzepatide are not rare, and Holly's description tracks closely with what clinical trials actually reported. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found nausea in roughly 30-45% of participants depending on dose, with vomiting in around 25%. These effects were most pronounced in the first few weeks and after dose escalations.
Four kilos in one week from side effects is on the high end, but not impossible when severe nausea and vomiting cause both reduced intake and fluid loss. That said, rapid weight loss of this kind is not the goal and is not the same as the gradual, sustained fat loss the drug is actually designed to produce.
The gut sounds she describes, technically called borborygmi, are consistent with tirzepatide's mechanism. The drug slows gastric emptying significantly, which means food sits in the GI tract longer, producing exactly the kind of gurgling and noise she's describing. This is pharmacology, not a malfunction.
What did they get wrong (or right)?
Holly gets more right than wrong here, but there are a couple of things worth addressing directly.
She's right that pushing through severe side effects isn't always the answer. The "just suffer through it" advice circulating on social media is not evidence-based. Dose titration exists precisely to reduce this kind of reaction. If she started at a higher dose or escalated too quickly, that's a clinical conversation she should be having with a prescriber, not something to white-knuckle through alone.
Where her framing gets slightly muddled: losing appetite entirely is a known effect, but the concern she raises about permanently losing enjoyment of food is not well-supported by the evidence. Davies et al. (2021, The Lancet) and subsequent real-world data suggest appetite suppression is dose-dependent and reversible. The drug does not rewire your relationship with food permanently.
The four-kilo loss being attributed entirely to side effects deserves scrutiny. Some of that is almost certainly water weight and reduced intake. Calling it a side-effect-only loss is partially accurate but a bit misleading about how the numbers break down.
What should you actually know?
If you're considering tirzepatide or you're in a similar situation to Holly's, a few things matter more than the anecdotes.
- Severe first-week GI symptoms are common but not inevitable. Starting at the lowest dose (2.5mg for tirzepatide) and titrating slowly over weeks is the standard clinical approach for a reason.
- If side effects are this debilitating, the right move is to contact your prescriber, not just stop or push through. Dose adjustment, anti-nausea medication, or a longer titration schedule are all real options.
- The appetite suppression Holly describes, where food becomes repulsive rather than just less appealing, can indicate the dose is too aggressive for her individual tolerance. This is a clinical signal, not a badge of the drug working harder.
- Weight loss from severe nausea and vomiting in week one is not meaningful fat loss. It does not represent what the drug does when used correctly.
- Stopping abruptly after one week is unlikely to cause harm, but it also means she's making a decision based on the hardest part of the adjustment curve, before the side effects typically ease.
The bigger picture on side effect severity
Holly's video is genuinely useful as a counterweight to the heavily curated "Mounjaro changed my life" content that dominates these hashtags. Not everyone has a smooth experience. The SURMOUNT trials showed meaningful dropout rates due to adverse events, and real-world tolerability can differ from controlled trial conditions.
What's missing from her video, through no fault of hers, is the clinical context: did she have a prescriber she could call this week? Was she given anti-emetics? Was her starting dose appropriate for her? Those are the questions that actually determine whether her week had to be this bad. The drug's side effect profile is real. Whether it had to be this severe is a separate question.